BACKGROUND: Although the clinical attributes of severe asthma in children have been well described, the differentiating features of the lower airway inflammatory response are less understood. OBJECTIVES: We sought to discriminate severe from moderate asthma in children by applying linear discriminant analysis, a supervised method of high-dimensional data reduction, to cytokines and chemokines measured in the bronchoalveolar lavage (BAL) fluid and alveolar macrophage (AM) lysate. METHODS: Bronchoalveolar lavage fluid was available from 53 children with asthma (severe asthma, n = 31) undergoing bronchoscopy for clinical indications and 30 nonsmoking adults. Twenty-three cytokines and chemokines were measured by using bead-based multiplex assays. Linear discriminant analyses of the BAL fluid and AM analytes were performed to develop predictive models of severe asthma in children. RESULTS: Although univariate analysis of single analytes did not differentiate severe from moderate asthma in children, linear discriminant analyses allowed for near complete separation of the moderate and severe asthmatic groups. Significant correlations were also noted between several of the AM and BAL analytes measured. In the BAL fluid, IL-13 and IL-6 differentiated subjects with asthma from controls, whereas growth-related oncogene (CXCL1), RANTES (CCL5), IL-12, IFN-gamma, and IL-10 best characterized severe versus moderate asthma in children. In the AM lysate, IL-6 was the strongest discriminator of all the groups. CONCLUSION: Severe asthma in children is characterized by a distinct airway molecular phenotype that does not have a clear T(H)1 or T(H)2 pattern. Improved classification of children with severe asthma may assist with the development of targeted therapeutics for this group of children who are difficult to treat. Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
BACKGROUND: Although the clinical attributes of severe asthma in children have been well described, the differentiating features of the lower airway inflammatory response are less understood. OBJECTIVES: We sought to discriminate severe from moderate asthma in children by applying linear discriminant analysis, a supervised method of high-dimensional data reduction, to cytokines and chemokines measured in the bronchoalveolar lavage (BAL) fluid and alveolar macrophage (AM) lysate. METHODS: Bronchoalveolar lavage fluid was available from 53 children with asthma (severe asthma, n = 31) undergoing bronchoscopy for clinical indications and 30 nonsmoking adults. Twenty-three cytokines and chemokines were measured by using bead-based multiplex assays. Linear discriminant analyses of the BAL fluid and AM analytes were performed to develop predictive models of severe asthma in children. RESULTS: Although univariate analysis of single analytes did not differentiate severe from moderate asthma in children, linear discriminant analyses allowed for near complete separation of the moderate and severe asthmatic groups. Significant correlations were also noted between several of the AM and BAL analytes measured. In the BAL fluid, IL-13 and IL-6 differentiated subjects with asthma from controls, whereas growth-related oncogene (CXCL1), RANTES (CCL5), IL-12, IFN-gamma, and IL-10 best characterized severe versus moderate asthma in children. In the AM lysate, IL-6 was the strongest discriminator of all the groups. CONCLUSION: Severe asthma in children is characterized by a distinct airway molecular phenotype that does not have a clear T(H)1 or T(H)2 pattern. Improved classification of children with severe asthma may assist with the development of targeted therapeutics for this group of children who are difficult to treat. Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Authors: Borja G Cosío; Buphinder Mann; Kazuhiro Ito; Elen Jazrawi; Peter J Barnes; K Fan Chung; Ian M Adcock Journal: Am J Respir Crit Care Med Date: 2004-04-15 Impact factor: 21.405
Authors: Anne M Fitzpatrick; W Gerald Teague; Fernando Holguin; Mary Yeh; Lou Ann S Brown Journal: J Allergy Clin Immunol Date: 2009-01 Impact factor: 10.793
Authors: Jacques de Blic; Isabelle Tillie-Leblond; André Bernard Tonnel; Francis Jaubert; Pierre Scheinmann; Philippe Gosset Journal: J Allergy Clin Immunol Date: 2004-01 Impact factor: 10.793
Authors: Anne M Fitzpatrick; Susan T Stephenson; Graham R Hadley; Leandrea Burwell; Madhuri Penugonda; Dawn M Simon; Jason Hansen; Dean P Jones; Lou Ann S Brown Journal: J Allergy Clin Immunol Date: 2011-04-22 Impact factor: 10.793
Authors: Anne M Fitzpatrick; W Gerald Teague; Deborah A Meyers; Stephen P Peters; Xingnan Li; Huashi Li; Sally E Wenzel; Shean Aujla; Mario Castro; Leonard B Bacharier; Benjamin M Gaston; Eugene R Bleecker; Wendy C Moore Journal: J Allergy Clin Immunol Date: 2010-12-31 Impact factor: 10.793
Authors: Lyndsey M Muehling; Peter W Heymann; Paul W Wright; Jacob D Eccles; Rachana Agrawal; Holliday T Carper; Deborah D Murphy; Lisa J Workman; Carolyn R Word; Sarah J Ratcliffe; Brian J Capaldo; Thomas A E Platts-Mills; Ronald B Turner; William W Kwok; Judith A Woodfolk Journal: J Allergy Clin Immunol Date: 2020-04-19 Impact factor: 10.793
Authors: Jocelyn R Grunwell; Susan T Stephenson; Rabindra Tirouvanziam; Lou Ann S Brown; Milton R Brown; Anne M Fitzpatrick Journal: J Allergy Clin Immunol Pract Date: 2018-09-05
Authors: Sheena D Brown; Katherine M Baxter; Susan T Stephenson; Annette M Esper; Lou Ann S Brown; Anne M Fitzpatrick Journal: J Allergy Clin Immunol Date: 2011-12-28 Impact factor: 10.793
Authors: Anne M Fitzpatrick; Susan T Stephenson; Milton R Brown; Khristopher Nguyen; Shaneka Douglas; Lou Ann S Brown Journal: J Allergy Clin Immunol Pract Date: 2016-09-21
Authors: Stanley J Szefler; James F Chmiel; Anne M Fitzpatrick; George Giacoia; Thomas P Green; Daniel J Jackson; Heber C Nielsen; Wanda Phipatanakul; Hengameh H Raissy Journal: J Allergy Clin Immunol Date: 2013-11-28 Impact factor: 10.793
Authors: Aimee Hoskins; Sara Reiss; Pingsheng Wu; Ning Chen; Wei Han; Rui-hong Do; Rasul Abdolrasulnia; Ryszard Dworski Journal: Am J Respir Crit Care Med Date: 2012-11-29 Impact factor: 21.405